Thrombin Generation Parameters and Bleeding in Patients Treated With Anticoagulants for Cancer Associated Thrombosis

Inclusion Criteria: * Patients with active cancer, as defined by current French recommendations (Mahé I et al Rev Mal Respir 2021) * Presenting acute proximal deep vein thrombosis of the lower limb (DVT) and/or proximal pulmonary embolism (at least segmental) (PE), confirmed by objective tests (Doppler ultrasound in the event of DVT; lung scintigraphy or CT scan in the event of PE) * No contraindication for anticoagulant treatment at a curative dose at the time of inclusion Exclusion Criteria: * Patients participating in a therapeutic clinical trial with a blinded therapy or an open-label therapeutic trial who are included in the experimental treatment group. * Patients already on anticoagulant at a curative dose for valvular or rhythmic embolic disease or a history of venous thromboembolic disease * Hematological malignancies * Patients with a contraindication to anticoagulant treatment on inclusion * Patient whose relay by DOAC has already been carried out.